SK Bioscience (302440) financial statements

+188.7%since 2020
FY2025 revenue
₩651.4B▲ +143.5%
FY2025 net income
−₩57.4B
FY2025 diluted EPS
−₩733.00
FY2025 free cash flow
−₩80.6B

SK Bioscience income statement

SK Bioscience income statement
KRW millionsFY2025FY2024FY2023
Period ended31 Dec 202531 Dec 202431 Dec 2023
Revenue651,368267,545369,506
Gross profit75,92430,976142,243
Operating income-123,502-138,431-11,988
Pretax income-85,860-89,1077,327
Net income-57,424-53,88122,318
Diluted earnings per share-733.00-698.00290.00

SK Bioscience balance sheet

SK Bioscience balance sheet
KRW millionsFY2025FY2024FY2023
Period ended31 Dec 202531 Dec 202431 Dec 2023
Cash and cash equivalents105,553312,702127,026
Total assets2,955,7442,843,5961,852,439
Total liabilities918,289821,144148,584
Total equity2,037,4542,022,4521,703,855
Long-term debtn/an/a0

SK Bioscience cash flow statement

SK Bioscience cash flow statement
KRW millionsFY2025FY2024FY2023
Period ended31 Dec 202531 Dec 202431 Dec 2023
Operating cash flow102,507-128,02029,346
Capital expenditure-183,091-164,413-43,441
Free cash flow (derived)-80,584-292,433-14,095

Quarterly highlights

Quarterly highlights
KRW millionsQ2 FY2026Q1 FY2026Q4 FY2025Q3 FY2025
Period ended30 Jun 202631 Mar 202631 Dec 202530 Sep 2025
Revenue (derived)155,705168,611184,186150,765
Operating income (derived)-15,738-44,535-51,610-19,371
Net income (derived)-17,888-33,327-57,96224,479
Diluted earnings per share-229.00-425.00n/a313.00
Operating cash flow (derived)2,682-42,53223,66520,652
Total assets2,981,7932,991,8862,955,7442,922,779

SK Bioscience major shareholders

SK Bioscience major shareholders
HolderShare of classSharesFiled
SK케미칼66.7%52,351,74726 March 2026

SK Bioscience DART filings

SK Bioscience DART filings
FiledFormType
12 August 2026Semiannual ReportHalf-year report
12 May 2026Quarterly ReportQuarterly report
27 April 2026Major Matters ReportCurrent report
12 March 2026Business ReportAnnual report
12 November 2025Quarterly ReportQuarterly report
11 August 2025Semiannual ReportHalf-year report
13 May 2025Quarterly ReportQuarterly report
16 March 2025Business ReportAnnual report

Common questions

What was SK Bioscience's revenue in fiscal 2025?

SK Bioscience reported ₩651.4 billion in revenue for fiscal 2025, the year ended 31 December 2025, up 143.5% from fiscal 2024.

What was SK Bioscience's net income in fiscal 2025?

SK Bioscience reported a net loss of ₩57.4 billion for fiscal 2025, the year ended 31 December 2025. Diluted earnings per share were −₩733.00.

What was SK Bioscience's free cash flow in fiscal 2025?

SK Bioscience had negative free cash flow of ₩80.6 billion in fiscal 2025. Operating cash flow was ₩102.5 billion and capital expenditure was ₩183.1 billion.

What were SK Bioscience's total assets at the end of fiscal 2025?

SK Bioscience reported total assets of ₩3.0 trillion at the end of fiscal 2025, the year ended 31 December 2025.

How much SK Bioscience history do I get?

Every account gets the full history, annual and quarterly, with first reported values and as of dates.